[Corrigendum] Neuroprotective effect of emodin against Alzheimer's disease via Nrf2 signaling in U251 cells and APP/PS1 mice.

Subsequently to the publication of this paper, an interested reader drew to the authors' attention that the lower left panel of Fig. 3A of this paper had already featured in the following paper, which featured one of the same authors (Zhiping Li): Zhang Y, Wang J, Wang C, Li Z, Liu X, Zhang J, Lu J and Wang D: Pharmacological basis for the use of evodiamine in Alzheimer's disease: antioxidation and antiapoptosis. Int J Mol Sci 21: 1527, 2018. Moreover, an independent analysis of the data in this paper conducted by the Editorial Office revealed that the Bcl‑2 protein western blotting data featured in Fig. 3C had apparently also appeared in a previous publication featuring the same author [Qiu Y, Jiang X, Liu D, Deng Z, Hu W, Li Z and Li Y: The hypoglycemic and renal protection properties of crocin via oxidative stress‑regulated NF‑κB signaling in db/db mice. Front Pharmacol 30: 541, 2020].  After having examined their original data, the authors have realized that Fig. 3 in the above paper had been inadvertently assembled incorrectly, owing to the mishandling of certain of the data. In addition, the authors wished to present a revised version of Fig. 4 containing more representative data for Fig. 4C and D. The corrected versions of Figs. 3 and 4, featuring the correct data for Fig. 3A and C, and the revised data in Fig. 4C and D, are shown on the next two pages. Note that these errors did not significantly affect the results or the conclusions reported in this paper, and all the authors agree to the publication of this Corrigendum. The authors are grateful to the Editor of for granting them the opportunity to publish this corrigendum, and apologize to the readership for any inconvenience caused. [Molecular Medicine Reports 23: 108, 2021; DOI: 10.3892/mmr.2020.11747].